Deadly E. Coli Bacteria Remains an Important Threat to U.S. Health According to New Study.

MAYWOOD, N.J. -- Nymox (NASDAQ:NYMX) NXC-4720 Product Can Substantially Reduce E. Coli O157:H7 Meat Contamination

Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) proprietary NXC-4720 product for the treatment of potentially fatal E. coli O157:H7 contamination has proven effective in reducing the level of contamination on fresh beef by 99% according to laboratory studies. Despite efforts to improve the safety of the U.S. food supply, outbreaks of potentially deadly E. coli O157 food contamination remain common according to a new study by researchers at the Centers for Disease Control (CDC) (Emerging Infectious Diseases April 2005 11:603- 609). The researchers found that from 1982 to 2002, a total of 350 E. coli O157 outbreaks spanning 49 states were reported to the CDC; many outbreaks went unrecognized or unreported. While ground beef was the most common source of outbreaks, other sources such as produce, dairy products, drinking water and animal contact were also significant. According to the study, E. coli O157 infection each year in the U.S. causes an estimated 73,480 illnesses, leading to an estimated 2,168 hospitalizations and 61 deaths and creating an important cause of acute kidney failure in children.

E. coli O157 contamination is a serious problem for the meat packing industry. One United States Department of Agriculture (USDA) study estimated the direct and indirect costs of foodborne E. coli O157 infections at over $650 million per year. In 2002 alone, over 23 million pounds of meat were recalled in the U.S. because of possible E. coli contamination, affecting all sectors of the meat industry from large meat processors to local supermarkets and many consumers. On average, Americans consume over 65 pounds of beef per person per year.

E. coli O157:H7 bacterial contamination is a major public health problem throughout the world. This type of E. coli infection can cause severe bloody diarrhea and abdominal cramps and can lead to kidney failure, particularly in young children and in the elderly, with often serious long term and sometimes fatal results.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox developed AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease. The AlzheimAlert(TM) test has CLIA approval in the U.S. and recently received the CE Mark making it eligible for sale in European countries. The Company has successfully completed two U.S. Phase 1 and Phase 1-2 clinical trials for NX-1207, its drug for benign prostatic hyperplasia (BPH). The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox has a number of drugs in development for Alzheimer's disease, oncology, and infectious disease.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.